cerca CERCA
Martedì 23 Aprile 2024
Aggiornato: 11:54
10 ultim'ora BREAKING NEWS

marketing

comunicato stampa

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

AMSTERDAM, April 15, 2024 /PRNewswire/ -- Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine's efforts to deliver patient access to eflornithine and bring a further treatment option in the field of paediatric oncology.

comunicato stampa

Isotopia Molecular Imaging Ltd. is thrilled to announce that Isoprotrace®, has received marketing authorization in the Netherlands (RVG 130527)

PETACH TIKVA, Israel, March 28, 2024 /PRNewswire/ -- Isotopia Molecular Imaging Ltd. is thrilled to announce that Isoprotrace®, our PSMA -11 kit, has received marketing authorization in the Netherlands (RVG 130527). This landmark approval marks a significant milestone in our ongoing commitment to improve healthcare and patient outcomes across the globe.



SEGUICI SUI SOCIAL



threads whatsapp linkedin twitter youtube facebook instagram
ora in
Prima pagina
articoli
in Evidenza